The fact that silencing of IL-13Rα2 inhibited invasion of HS766T cells in a Matrigel invasion assay [101] points out that IL-13Rα2 may be a therapeutic target for pancreatic cancer treatment. Here, IL13RA2 is linked to pancreatic neoplasm.